Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

AimsWe compared the effects of continuous subcutaneous insulin infusion (CSII) with those of multiple daily insulin (MDI) injections on glycaemic control, risk of hypoglycaemic episodes, insulin requirements and adverse events in type 1 and type 2 diabetes mellitus.MethodsThe electronic databases MEDLINE, EMBASE and CENTRAL were systematically searched for randomised controlled trials up to March 2007. A systematic review and meta-analysis were performed.ResultsOverall, 22 studies were included (17 on type 1 diabetes mellitus, two on type 2 diabetes mellitus, three on children). With regard to adults with type 1 diabetes mellitus, our meta-analysis found a between-treatment difference of −0.4% HbA1c (six studies) in favour of CSII therapy. Available median rates of mild or overall hypoglycaemic events were comparable between the different interventions (1.9 [0.9–3.1] [CSII] vs 1.7 [1.1–3.3] [MDI] events per patient per week). Total daily insulin requirements were lower with CSII than with MDI therapy. In patients with type 2 diabetes mellitus, CSII and MDI treatment showed no statistically significant difference for HbA1c. The incidence of mild hypoglycaemic events was comparable between the treatment groups. In adolescents with type 1 diabetes mellitus, glycated haemoglobin and insulin requirements were significantly lower in the CSII groups; no data were available on hypoglycaemic events. The only study performed in younger children did not provide enough data for conclusive inferences. No overall conclusions were possible for severe hypoglycaemia and adverse events for any of the different patient groups due to rareness of such events, different definitions and insufficient reporting.Conclusions/interpretationCSII therapy in adults and adolescents with type 1 diabetes mellitus resulted in a greater reduction of glycated haemoglobin, in adult patients without a higher rate of hypoglycaemia. No beneficial effect of CSII therapy could be detected for patients with type 2 diabetes mellitus.

[1]  G. Forlani,et al.  Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. , 1985, Diabete & metabolisme.

[2]  T R Pieber,et al.  Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. , 2006, The Cochrane database of systematic reviews.

[3]  D. Bruttomesso,et al.  Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[4]  K. Dahl-Jørgensen,et al.  Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. , 1986, British medical journal.

[5]  K. Dahl-Jørgensen.  Near-normoglycemia and late diabetic complications , 1987 .

[6]  R. Sharpe,et al.  Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the rat. , 1988, The Journal of endocrinology.

[7]  F. Schmidt.  Meta-Analysis , 2008 .

[8]  K. Dahl-Jørgensen,et al.  Glomerular charge selectivity and the influence of improved blood glucose control in Type 1 (insulin-dependent) diabetic patients with microalbuminuria , 1992, Diabetologia.

[9]  I Guilhem,et al.  Technical risks with subcutaneous insulin infusion. , 2006, Diabetes & metabolism.

[10]  K. Dahl-Jørgensen,et al.  Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. , 1988, Acta endocrinologica.

[11]  H. Beck-Nielsen,et al.  Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment , 1989, European journal of clinical investigation.

[12]  K. Dahl-Jørgensen,et al.  Oscillatory potentials, macular recovery time, and diabetic retinopathy through 3 years of intensified insulin treatment. , 1988, Ophthalmology.

[13]  K. Alberti,et al.  A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. , 1982, Diabetes care.

[14]  N. Saurbrey,et al.  Comparison of Continuous Subcutaneous Insulin Infusion with Multiple Insulin Injections Using the NovoPen , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[15]  D. Kerr,et al.  Skin-related complications of insulin therapy: epidemiology and emerging management strategies. , 2003, American journal of clinical dermatology.

[16]  D J Rowlands,et al.  A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. , 2004, Health technology assessment.

[17]  S. Mudaliar,et al.  Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. , 2003, Diabetes care.

[18]  R. Heine,et al.  A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. , 2002, Diabetes care.

[19]  K. Dahl-Jørgensen,et al.  Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. , 1985, British medical journal.

[20]  Ray Burke,et al.  A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. , 2005, Diabetes care.

[21]  P. Hersh,et al.  A One--year Prospective Study , 1992 .

[22]  I. Mühlhauser,et al.  Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience , 1989, Diabetologia.

[23]  K. Dahl-Jørgensen.  Near-normoglycemia and late diabetic complications. The Oslo Study. , 1987, Acta endocrinologica. Supplementum.

[24]  K. Dahl-Jørgensen,et al.  Effects of intensified insulin treatment on various lesions of diabetic retinopathy. , 1985, American journal of ophthalmology.

[25]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[26]  K. Dahl-Jørgensen,et al.  Increase in Insulin Antibodies During Continuous Subcutaneous Insulin Infusion and Multiple-Injection Therapy in Contrast to Conventional Treatment , 1987, Diabetes.

[27]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[28]  B. Zinman,et al.  Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. , 2004, Diabetes care.

[29]  J. Tauber,et al.  Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. , 2000, Diabetes care.

[30]  B. Zinman,et al.  Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. , 2001, Diabetes care.

[31]  T. Erlinger,et al.  Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. , 2003, Diabetes care.

[32]  H. Beck-Nielsen,et al.  Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. , 1987, Diabetes research.

[33]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[34]  P. Allhoff,et al.  The Oslo Study , 1991 .

[35]  R. Mecklenburg,et al.  Factors Related to Discontinuation of Continuous Subcutaneous Insulin-Infusion Therapy , 1988, Diabetes Care.

[36]  Darrell M. Wilson,et al.  A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. , 2005, Diabetes care.

[37]  N. Waugh,et al.  Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. , 2004, Health technology assessment.

[38]  H Keen,et al.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. , 1978, British medical journal.

[39]  John Pickup,et al.  Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials , 2002, BMJ : British Medical Journal.

[40]  A. Schiffrin,et al.  Feasibility of strict diabetes control in insulin-dependent diabetic adolescents. , 1983, The Journal of pediatrics.

[41]  A. Schiffrin,et al.  Intensified Insulin Therapy in the Type I Diabetic Adolescent: A Controlled Trial , 1984, Diabetes Care.

[42]  W. Tamborlane,et al.  A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. , 2004, Diabetes care.

[43]  P. Hamet,et al.  Continuous Subcutaneous Insulin Infusion (Mill-Hill Infuser) Versus Multiple Injections (Medi-Jector) in the Treatment of Insulin-dependent Diabetes Mellitus and the Effect of Metabolic Control on Microangiopathy , 1984, Diabetes Care.

[44]  H. Tritschler,et al.  Hydroperoxides in Plasma Are Reduced by Intensified Insulin Treatment: A randomized controlled study of IDDM patients with microalbuminuria , 1998, Diabetes Care.

[45]  A. Galatzer,et al.  Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients. , 1985, Israel journal of medical sciences.

[46]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[47]  R. Osterby,et al.  Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy , 1994, Diabetologia.

[48]  K. Hermansen,et al.  Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM). , 1989, Danish medical bulletin.

[49]  J. Weissberg-Benchell,et al.  Insulin pump therapy: a meta-analysis. , 2003, Diabetes care.

[50]  A. Schiffrin,et al.  Comparison Between Continuous Subcutaneous Insulin Infusion and Multiple Injections of Insulin: A One-Year Prospective Study , 1982, Diabetes.

[51]  I. Hirsch,et al.  Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.